Editorial
doi: 10.1111/apt.16921.
Editorial: liver and kidney injury from remdesivir-an issue not as much as its purpose
Affiliations
- PMID: 35538355
- DOI: 10.1111/apt.16921
Item in Clipboard
Editorial
Editorial: liver and kidney injury from remdesivir-an issue not as much as its purpose
Aliment Pharmacol Ther.
2022 Jun.
No abstract available
Comment in
-
Editorial: liver and kidney injury from remdesivir-an issue not as much as its purpose. Authors' reply.Aliment Pharmacol Ther. 2022 Jun;55(11):1457-1458. doi: 10.1111/apt.16932. Aliment Pharmacol Ther. 2022. PMID: 35538354 No abstract available.
Comment on
-
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.Aliment Pharmacol Ther. 2022 Jul;56(1):121-130. doi: 10.1111/apt.16894. Epub 2022 Mar 22. Aliment Pharmacol Ther. 2022. PMID: 35318694 Free PMC article.
Similar articles
-
Editorial: liver and kidney injury from remdesivir-an issue not as much as its purpose. Authors' reply.Aliment Pharmacol Ther. 2022 Jun;55(11):1457-1458. doi: 10.1111/apt.16932. Aliment Pharmacol Ther. 2022. PMID: 35538354 No abstract available.
-
Remdesivir-Induced Liver Injury in a COVID-Positive Newborn.Indian J Pediatr. 2022 Aug;89(8):826. doi: 10.1007/s12098-022-04237-6. Epub 2022 May 18. Indian J Pediatr. 2022. PMID: 35583631 Free PMC article. No abstract available.
-
Remdesivir Use in COVID-19 Patients: Cutaneous Adverse Effect or Disease Manifestation?J Drugs Dermatol. 2021 May 1;20(5):575. doi: 10.36849/JDD.5777. J Drugs Dermatol. 2021. PMID: 33938699 No abstract available.
-
Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.J Am Soc Nephrol. 2020 Jul;31(7):1384-1386. doi: 10.1681/ASN.2020050589. Epub 2020 Jun 8. J Am Soc Nephrol. 2020. PMID: 32513665 Free PMC article. Review. No abstract available.
-
Remdesivir-COVID-19: drug interactions in dentistry.Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9739-9743. doi: 10.26355/eurrev_202009_23065. Eur Rev Med Pharmacol Sci. 2020. PMID: 33015819 Review.
References
REFERENCES
-
- https://www.gilead.com/-/media/files/pdfs/medicines/COVID-19/veklury/vek... (accessed 19 March 2022).
-
- Wong CKH, Au ICH, Cheng WY, Man KKC, Lau KTK, Mak LY, et al. Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalized with COVID-19: a self-controlled case series study. Aliment Pharmacol Ther. 2022; DOI: 10.1111/apt.16894
-
- Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515.